Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys in HBeAg-positive chronic hepatitis B
NCT00048945Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2002
- Primary completion
- Oct 2004
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of pegylated interferon alpha in Chronic Hepatitis B (CHB) (3 arms), sponsored by Roche. Primary endpoints: HBeAg seroconversion at 72 weeks, HBV DNA suppression at 72 weeks and 1 more. Started Jan 2002; status: completed.
02
Drugs
pegylated interferon alpha
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00048945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048945.